Back to News
Market Impact: 0.48
Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesCompany Fundamentals
CagriSema 1.0 mg/1.0 mg delivered 12.4% weight loss at week 60 in adults with type 2 diabetes, exceeding the 9.1% achieved by tirzepatide 5 mg. The treatment also achieved non-inferior HbA1c reduction, supporting its potential competitive positioning in the diabetes and obesity-treatment markets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- RIP the Cybertruck: Elon Musk says Tesla will wind down production of its most polarizing EV
- Tesla will stop making the Cybertruck in 2027
- Tesla is 'winding down' Cybertruck production at its Texas Gigafactory
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Tesla is ‘winding down’ production of the Cybertruck next year